Clinical trials have been held using activators of Cxs and Panx channels such as rotigaptide for treating atrial fibrillation (NCT00137332) and endothelial dysfunction (NCT00901563), and Cx43 inhibitors for the treatment of severe ocular surface burns. The gene discussed is GJA1; the disease is endothelial dysfunction.